Last Update 03 Mar 26

Fair value Increased 2.37%

ARGX: Expanded Neuromuscular Indications Will Drive Long Term Upside Potential

The analyst fair value estimate for argenx edges up from €825.51 to €845.07, as analysts trim long term growth and margin assumptions while still pointing to Vyvgart uptake, late stage pipeline breadth, and ongoing price targets mostly above the current level as key supports for the updated price target range.

Analyst Commentary

Recent Street research shows a mixed but generally constructive tone around argenx, with price targets adjusted both up and down while ratings largely stay positive. Analysts are weighing Vyvgart execution, pipeline breadth, and long term spending plans as they refine their models.

Bullish Takeaways

Bullish analysts point to Vyvgart as a core value driver, highlighting continued growth following the PFS launch and a franchise that is now described as annualizing over US$5b in global revenue. They see this as supportive for current premium valuations.
Several research notes emphasize breadth in late stage development, with references to around 20 Phase II/III trials and three potential registrational readouts in 2026, which they view as strengthening the durability of argenx's growth profile.
Positive Phase 3 data in ocular myasthenia gravis and commentary around expansion into seronegative MG and other indications are framed as relatively low risk commercial extensions that could add to the Vyvgart opportunity over time.
Even where price targets are trimmed, bullish analysts continue to use language consistent with buy or overweight stances. This reflects confidence in execution and, in one case, long term upside potential to a significantly higher market capitalization.

Bearish Takeaways

Bearish analysts focus on reduced price targets, indicating that updated models now embed more conservative long term growth and margin assumptions. This feeds into a lower fair value range despite continued optimism on the product and pipeline.
Some commentary cites management's Q1 and operating expense outlook as a pressure point for the shares, suggesting that higher spending or slower cost leverage could weigh on near term sentiment and valuation multiples.
There are references to increasing competition and Q1 seasonality around the Vyvgart franchise, which more cautious voices flag as potential sources of volatility for both revenue trajectories and investors' expectations.
A few research notes imply that consensus estimates, such as those for 2026 revenue, may be too conservative or too aggressive depending on the read. This underscores that execution against guidance and clinical timelines remains a key swing factor for the stock's valuation range.

What's in the News

argenx reported positive topline Phase 3 ADAPT OCULUS results for VYVGART in adults with ocular myasthenia gravis, with a 4.04 point improvement in MGII PRO ocular scores at Week 4 for treated patients versus 1.99 for placebo, and plans to present the data at an upcoming medical meeting and submit to the U.S. FDA by the end of Q3 2026 (company announcement).
The U.S. FDA accepted a priority review for a supplemental Biologics License Application for VYVGART to treat adults with acetylcholine receptor antibody seronegative generalized myasthenia gravis, supported by Phase 3 ADAPT SERON data showing statistically significant improvement in MG ADL scores versus placebo after four weeks, with a PDUFA target action date of May 10, 2026 (company announcement).
argenx decided to discontinue the Phase 3 UplighTED trials of subcutaneous efgartigimod in adults with moderate to severe thyroid eye disease after an Independent Data Monitoring Committee recommended stopping for futility following an interim analysis, while reporting a favorable safety and tolerability profile and no new safety signals, and planning a full data analysis and future data presentation (company announcement).
The company announced a leadership change, with current Chief Operating Officer Karen Massey set to become Chief Executive Officer and current CEO Tim Van Hauwermeiren moving to a non Executive Director role and Chairman of the Board, following Massey’s role in accelerating the VYVGART launch and building the commercial organization (company announcement).

Valuation Changes

Fair Value: edged up slightly from €825.51 to €845.07, reflecting a modest recalibration of the valuation range.
Discount Rate: moved marginally higher from 5.69% to 5.73%, implying a slightly higher required return in the updated model.
Revenue Growth: trimmed from 30.87% to 25.62%, indicating more conservative long term revenue expectations.
Net Profit Margin: adjusted down from 38.13% to 35.11%, pointing to a somewhat lower projected level of long run profitability.
Future P/E: raised from 22.7x to 25.1x, suggesting a higher earnings multiple applied to the updated earnings stream.

16 views

Key Takeaways

Broadening indications and effective global expansion for Vyvgart, alongside pipeline progress, are driving strong, sustained revenue and margin growth.
Strategic partnerships and advances in disease targeting are expanding market opportunities and operational efficiencies, supporting long-term growth potential.
Intensifying competition, pricing pressures, and reliance on a single product threaten argenx's profitability amid increasing rebate burdens and ongoing uncertainty in drug reimbursement.

Catalysts

About argenx

A commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.What are the underlying business or industry changes driving this perspective?

The global increase in autoimmune and chronic diseases due to population aging continues to expand the long-term addressable patient population for argenx's therapies, supporting sustainable multi-year revenue growth as Vyvgart and future pipeline assets gain additional indications and market penetration.
Ongoing expansion of Vyvgart into new indications (e.g., CIDP, seronegative MG, ocular MG) and geographies, along with strong uptake of self-administered formulations like the prefilled syringe, is driving durable volume/revenue growth and enabling operational leverage that could materially benefit net margins as the company scales.
Successful advancement of a robust pipeline with multiple late-stage trials across diverse autoimmune conditions (e.g., empasiprubart and ARGX-119) enhances the probability of delivering multiple blockbuster therapies, providing visibility into future top-line and earnings expansion that is not fully reflected in the current valuation.
Strategic collaborations (e.g., with Unnatural Products for AI-driven peptide discovery and regional partners for global commercialization) are increasing operational efficiency, reducing commercial risk, and may boost long-term profitability through margin expansion and accelerated entry into emerging markets.
Advances in genomic and proteomic profiling and increased global healthcare spending are enabling identification and targeting of additional rare and difficult-to-treat diseases, aligning with argenx's focus and creating opportunities for sustained long-term growth in revenues and earnings as the product portfolio expands.

argenx Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming argenx's revenue will grow by 30.6% annually over the next 3 years.
Analysts assume that profit margins will shrink from 41.0% today to 38.0% in 3 years time.
Analysts expect earnings to reach $2.6 billion (and earnings per share of $40.61) by about September 2028, up from $1.3 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $3.6 billion in earnings, and the most bearish expecting $1.4 billion.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 23.5x on those 2028 earnings, down from 34.0x today. This future PE is lower than the current PE for the GB Biotechs industry at 33.9x.
Analysts expect the number of shares outstanding to grow by 1.8% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 5.26%, as per the Simply Wall St company report.

argenx Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Intensifying competition from both existing large pharmaceutical companies and new entrants, as highlighted by the frequent mentions of a "heating up" competitive environment (e.g., UPLIZNA and innovation coming to the MG and CIDP markets), may pressure argenx's market share and limit its ability to sustain premium pricing for VYVGART and future products-potentially impacting revenue growth and net margins.
Increasing gross-to-net adjustments, largely due to the Medicare Part D redesign and growing product mix complexity (specifically with expansion of the prefilled syringe), have increased discounts and rebates from 12% to ~20% within six months; while management says net revenue per patient is holding steady for now, further increases in gross-to-net (which they expect will "creep up") could pressure net margins and ultimately reduce earnings leverage if net price erosion occurs.
Heavy dependence on VYVGART as the principal revenue driver exposes the company to significant product concentration risk; any regulatory, safety (such as potential FAERS signal requiring label change), or competitive disruptions could sharply reduce both revenues and profitability, especially since expansion into other indications and pipeline diversification is still in early stages.
Persistent industry-wide scrutiny over drug pricing (notably Medicare/IRA-related negotiations and global pressure on reimbursement) creates longer-term uncertainty regarding the sustainability of high list-prices for novel biologics, which may lead to restrictive reimbursement, lower net realized prices, and dampen top-line revenue growth across key geographies (notably the US and EU).
Despite robust operational and early commercial performance, argenx's ongoing high R&D and SG&A spending (Q2 expenses totaled $766M, with R&D at $328M and SG&A at $325M) combined with the need for large-scale investment in supply chain and potential acquisitions means profitability and cash flow could be pressured if new pipeline launches are delayed or fail to achieve commercial success-negatively affecting net margins and earnings trajectory.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of €712.238 for argenx based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €885.0, and the most bearish reporting a price target of just €480.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $6.9 billion, earnings will come to $2.6 billion, and it would be trading on a PE ratio of 23.5x, assuming you use a discount rate of 5.3%.
Given the current share price of €610.4, the analyst price target of €712.24 is 14.3% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on argenx?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

ARGX: Upcoming Phase 3 Readouts and Expanded Access Will Shape Future Outlook